Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Buti

Showing results (51-60 of 386) with videos related to

Pageof 39
Sort By:
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|December 26, 2009
Are recipients of solid organ transplantation a high-risk population for hepatitis E virus infection?Maria Buti, Cecilia Cabrera, Rosendo Jardi, et al.
Current Opinion in Virology|November 12, 2018
HDV evolution-will viral resistance be an issue in HDV infection?David Tabernero, Maria Francesca Cortese, Maria Buti, et al.
Journal of Hepatology|March 10, 2024
Reply to: "Ultrasensitive HBsAg testing predicts HBsAg seroreversion outcomes: Considerations for new and existing therapies"Marc G Ghany, Maria Buti, Pietro Lampertico, et al.
JHEP Reports : Innovation in Hepatology|August 18, 2025
Hepatitis D epidemiology and access to diagnostic testing among healthcare providers in Africa: A multi-country surveyMaria Buti, C Wendy Spearman, Karin Siebelt, et al.
Journal of Hepatology|June 28, 2023
Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints ConferenceMarc G Ghany, Maria Buti, Pietro Lampertico, et al.
Expert Review of Clinical Pharmacology|September 11, 2018
The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugsCarlos Roncero, Jose Luis Villegas, Maria Martínez-Rebollar, et al.
Hepatology (Baltimore, Md.)|June 16, 2023
Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints ConferenceMarc G Ghany, Maria Buti, Pietro Lampertico, et al.
International Urology and Nephrology|November 8, 2007
De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infectionJose L Tovar, Maria Buti, Alfonso Segarra, et al.
Hepatology (Baltimore, Md.)|April 30, 2003
Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 casesMaria Buti, Auristela Valdés, Francisco Sánchez-Avila, et al.
Hepatology (Baltimore, Md.)|March 13, 2016
Baseline HCV-RNA levels in genotype 1 chronic hepatitis C patients: The role of different cut-off pointsMaria Buti, Juan J Sánchez-Ruano, Rosa M Morillas, et al.
Pageof 39

Showing results (51-60 of 386) with videos related to

Sort By:
Pageof 39
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|December 26, 2009
Are recipients of solid organ transplantation a high-risk population for hepatitis E virus infection?Maria Buti, Cecilia Cabrera, Rosendo Jardi, et al.
Current Opinion in Virology|November 12, 2018
HDV evolution-will viral resistance be an issue in HDV infection?David Tabernero, Maria Francesca Cortese, Maria Buti, et al.
Journal of Hepatology|March 10, 2024
Reply to: "Ultrasensitive HBsAg testing predicts HBsAg seroreversion outcomes: Considerations for new and existing therapies"Marc G Ghany, Maria Buti, Pietro Lampertico, et al.
JHEP Reports : Innovation in Hepatology|August 18, 2025
Hepatitis D epidemiology and access to diagnostic testing among healthcare providers in Africa: A multi-country surveyMaria Buti, C Wendy Spearman, Karin Siebelt, et al.
Journal of Hepatology|June 28, 2023
Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints ConferenceMarc G Ghany, Maria Buti, Pietro Lampertico, et al.
Expert Review of Clinical Pharmacology|September 11, 2018
The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugsCarlos Roncero, Jose Luis Villegas, Maria Martínez-Rebollar, et al.
Hepatology (Baltimore, Md.)|June 16, 2023
Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints ConferenceMarc G Ghany, Maria Buti, Pietro Lampertico, et al.
International Urology and Nephrology|November 8, 2007
De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infectionJose L Tovar, Maria Buti, Alfonso Segarra, et al.
Hepatology (Baltimore, Md.)|April 30, 2003
Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 casesMaria Buti, Auristela Valdés, Francisco Sánchez-Avila, et al.
Hepatology (Baltimore, Md.)|March 13, 2016
Baseline HCV-RNA levels in genotype 1 chronic hepatitis C patients: The role of different cut-off pointsMaria Buti, Juan J Sánchez-Ruano, Rosa M Morillas, et al.
Pageof 39